| TSBP1-AS1 |
|
TSBP1 and BTNL2 antisense RNA 1
|
|
|
0.638 |
0.692 |
44
|
49 |
| MIR4435-2HG |
|
MIR4435-2 host gene
|
|
|
0.604 |
0.692 |
38
|
56 |
| CASC15 |
|
cancer susceptibility 15
|
|
|
0.603 |
0.577 |
35
|
41 |
| CCDC26 |
Q8TAB7
|
CCDC26 long non-coding RNA
|
|
|
0.647 |
0.615 |
31
|
41 |
| PVT1 |
|
Pvt1 oncogene
|
|
|
0.495 |
0.731 |
27
|
31 |
| PCAT1 |
|
prostate cancer associated transcript 1
|
|
|
0.575 |
0.615 |
24
|
59 |
| HCP5 |
Q6MZN7
|
HLA complex P5
|
|
|
0.595 |
0.808 |
23
|
17 |
| MIR3936HG |
|
MIR3936 host gene
|
|
|
0.861 |
0.269 |
22
|
18 |
| CCDC162P |
|
coiled-coil domain containing 162, pseudogene
|
|
|
0.890 |
0.154 |
21
|
28 |
| LINC02210-CRHR1 |
P34998
|
LINC02210-CRHR1 readthrough
|
|
|
0.570 |
0.692 |
20
|
30 |
| MIR3681HG |
|
MIR3681 host gene
|
|
|
0.736 |
0.269 |
19
|
15 |
| IGF2-AS |
Q6U949
|
IGF2 antisense RNA
|
|
|
0.612 |
0.615 |
19
|
7 |
| BORCS7-ASMT |
|
BORCS7-ASMT readthrough (NMD candidate)
|
|
|
0.805 |
0.154 |
18
|
15 |
| PKN2-AS1 |
|
PKN2 antisense RNA 1
|
|
|
0.769 |
0.385 |
17
|
21 |
| LINC01478 |
|
long intergenic non-protein coding RNA 1478
|
|
|
1.000 |
0.077 |
17
|
15 |
| MEF2C-AS1 |
|
MEF2C antisense RNA 1
|
|
|
0.861 |
0.154 |
17
|
31 |
| LINC00598 |
|
long intergenic non-protein coding RNA 598
|
|
|
0.743 |
0.192 |
17
|
13 |
| CCND2-AS1 |
|
CCND2 antisense RNA 1
|
|
|
0.760 |
0.154 |
16
|
7 |
| LINC01505 |
|
long intergenic non-protein coding RNA 1505
|
|
|
0.821 |
0.192 |
15
|
25 |
| SPRY4-AS1 |
|
SPRY4 antisense RNA 1
|
|
|
0.890 |
0.192 |
15
|
15 |
| MIR29B2CHG |
|
MIR29B2 and MIR29C host gene
|
|
|
0.839 |
0.192 |
13
|
12 |
| LMCD1-AS1 |
|
LMCD1 antisense RNA 1
|
|
|
0.780 |
0.346 |
13
|
24 |
| LINC01524 |
|
long intergenic non-protein coding RNA 1524
|
|
|
0.839 |
0.192 |
13
|
16 |
| LINC01876 |
|
long intergenic non-protein coding RNA 1876
|
|
|
0.861 |
0.115 |
13
|
15 |